Olanzapine induced hyperprolactinemia

Veena Nayak, Virupaksha Devaramane, Deepak Mallya, Panambur V. Bhandary

Abstract


Olanzapine, a second generation antipsychotic is widely used for the treatment of schizophrenia and bipolar disorders. Though olanzapine is an efficacious antipsychotic it has been associated with many adverse effects like weight gain, hyperlipidemia, diabetes mellitus, etc necessitating its discontinuation. Here, we present two cases of hyperprolactinemia induced by olanzapine.


Keywords


Olanzapine, Atypical antipsychotic, Hyperprolactinemia

Full Text:

PDF

References


Marder SR, Hurford IM, Kammen DP. Second – Generation antipsychotics. In Sadock BJ, Sadock VA, Ruiz P, editors. Kaplan and Sadock’s comprehensive textbook of psychiatry 9th ed (Vol II). Philadelphia, Lippincott Williams and Wilkins, 2009:3206-3221.

Lieberman JA, Stroup TS. The NIMH-CATIE schizophrenia study: what did we learn? Am J Psychiatry. 2011;168(8):770-5.

Naranjo C, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30: 239-45.

Kingsbury SJ, Castelo C, Abulseoud O. Quetiapine foe olanzapine –induced galactorrhoea. Am J psychiatry 2002;159 (6):1061.

Hamner M. The effects of atypical antipsychotics on serum prolactin levels. Ann Clin Psychiatry 2007;14(3):163-73.

Canuso CM, Hanau M, Jhamb KK, Green AI. Olanzapine use in women with antipsychotic induced hyperprolactinemia. Am J psychiatry 1998;155(10):1458.